Walleye Capital LLC purchased a new position in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI – Get Rating) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 24,320 shares of the company’s stock, valued at approximately $858,000.
Other institutional investors also recently modified their holdings of the company. Zions Bancorporation N.A. bought a new stake in shares of Maravai LifeSciences in the 1st quarter valued at about $28,000. C M Bidwell & Associates Ltd. acquired a new stake in Maravai LifeSciences during the 1st quarter valued at approximately $38,000. SG Americas Securities LLC acquired a new position in shares of Maravai LifeSciences in the 4th quarter worth approximately $112,000. Point72 Hong Kong Ltd bought a new stake in shares of Maravai LifeSciences in the 1st quarter valued at $163,000. Finally, Bayesian Capital Management LP increased its position in shares of Maravai LifeSciences by 22.1% during the fourth quarter. Bayesian Capital Management LP now owns 5,245 shares of the company’s stock worth $220,000 after buying an additional 949 shares during the period. Institutional investors own 51.02% of the company’s stock.
Maravai LifeSciences Trading Down 0.7 %
NASDAQ:MRVI opened at $23.14 on Tuesday. Maravai LifeSciences Holdings, Inc. has a one year low of $19.83 and a one year high of $50.18. The company has a market cap of $5.91 billion, a PE ratio of 13.77 and a beta of 0.72. The company has a debt-to-equity ratio of 0.68, a current ratio of 6.75 and a quick ratio of 6.21. The firm has a 50-day moving average of $24.50 and a 200-day moving average of $29.92.
Wall Street Analyst Weigh In
About Maravai LifeSciences
Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.
- Get a free copy of the StockNews.com research report on Maravai LifeSciences (MRVI)
- Oracle’s Short-Term Pain Could Be Your Long-Term Gain
- Lucid is Looking Like a Clear EV Winner
- Still Lovin’ It: Investors Keep Visiting McDonald’s
- Did FedEx Just Deliver A Buying Opportunity?
- Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
Receive News & Ratings for Maravai LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maravai LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.